Goldman Sachs Maintains Buy on Veracyte, Lowers Price Target to $28
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Matthew Sykes maintains a Buy rating on Veracyte (NASDAQ:VCYT) but lowers the price target from $32 to $28.

April 15, 2024 | 2:33 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Goldman Sachs maintains a Buy rating on Veracyte but reduces the price target from $32 to $28.
While the reduction in price target could suggest a tempered outlook on Veracyte's short-term price potential, the maintenance of a Buy rating indicates continued confidence in the company's fundamentals. This mixed signal could lead to neutral short-term price movement as investors weigh the lowered price target against the ongoing endorsement.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100